top of page

Rome Therapeutics’ CEO on the science of the 'Dark Genome' and last week’s $72M Series B extension

Rosana Kapeller explains how Rome is looking at areas of the genome that do not encode for traditional proteins as the basis of disease and drug development.



Comentarios


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page